Limitations in randomised controlled trials evaluating drug effects in mania

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Increasing number of drugs evaluated for mania in randomized controlled trials (RCTs).
• Potential discrepancies exist between RCT recommendations and clinical practice for antimanic treatment.
• Concerns regarding the generalizability of RCT findings to patients in ordinary clinical practice.

Purpose of the Study:

• To address issues related to RCTs on drug effects in mania.
• To examine the impact of patient selection on the applicability of RCT results.
• To discuss the evaluation and interpretation of outcomes, including response criteria and drop-out rates.

Main Methods:

• Discussion of generalizability limitations in RCTs for mania.
• Analysis of various response criteria based on mania rating scale scores.
• Addressing high drop-out rates in mania drug trials.

Main Results:

• Generalizability of RCTs may be limited by pre-randomization selection criteria.
• The Bech-Rafaelsen Mania Rating Scale is sufficiently evaluated for dimensionality.
• A response defined by a score decline below a limit may offer advantages over the 50% reduction criterion.
• High drop-out rates (around 50%) are a significant issue in mania RCTs.

Conclusions:

• Open discussion of generalizability limitations is crucial in RCT reports.
• Rigorous placebo-controlled trials are necessary for efficacy, but pragmatic studies are needed for clinical practice insights.
• Large-scale pragmatic studies with broad inclusion criteria and relevant outcome measures are essential to understand treatment effectiveness in real-world settings.